Status:
RECRUITING
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Lead Sponsor:
Gulam Manji
Collaborating Sponsors:
Arcus Biosciences, Inc.
Conditions:
Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathwa...
Detailed Description
The overall objective of this study is to combine standard radiation therapy with drugs that stimulate the body's immune system against cancer cells (by targeting the protein programmed cell death (PD...
Eligibility Criteria
Inclusion
- Histological or pathological confirmation of pancreatic adenocarcinoma Cytologic or histologic proof of pancreatic ductal adenocarcinoma (PDAC) needs to be verified by the treating institution pathologist. A pathological report from non-treating institutions is sufficient to consent and to initiate investigational therapy if tissue sample is unavailable for evaluation at time of consent or enrollment. However, in such a case, PDAC diagnosis should be confirmed by the treating institution pathologist at a later time.
- Completed 8 cycles of neoadjuvant modified FOLFIRINOX. Omission of oxaliplatin due to adverse events may be allowed in cycles 5-8 with consultation with the principal investigator.
- Patients with surgically resectable PDAC who are considered appropriate to undergo the applicable operation.
- Eligible to undergo SBRT.
- Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- No prior surgical, systemic, or radiotherapy for PDAC except for mFOLFIRINOX.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Age ≥ 18 years.
- Adequate hematological and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of investigational treatment:
Exclusion
- Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including but not limited to anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies.
- Patients who are receiving any other investigational agents concurrently.
- Concomitant treatment with other anti-neoplastic agents (hormonal therapy acceptable).
- Uncontrolled pleural effusion, pericardial effusion, or ascites.
- Uncontrolled hypercalcemia (ionized calcium \> 1.5 mmol/L, calcium \> 12 mg/dL, or corrected serum calcium \> ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy.
- Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease (Crohn's disease or ulcerative colitis), antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis (some exceptions permissible as outlined per protocol).
- History of idiopathic pulmonary fibrosis, interstitial lung disease, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
- • History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- Positive HIV test at screening or at any time prior to screening.
- Active hepatitis B virus (HBV) infection (chronic or acute), defined as having a positive hepatitis B surface antigen (HBsAg) test at screening.
- -Note: Patients with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody test at screening, are eligible for the study.
- Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test followed by a positive HCV RNA test at screening. The HCV RNA test will be performed only for patients who have a positive HCV antibody test.
- Known clinically significant liver disease, including alcoholic hepatitis, cirrhosis, fatty liver disease, and inherited liver disease.
- Known active tuberculosis.
- Inability to swallow medication or malabsorption condition that would alter the absorption of orally administered medications.
- Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents and breastfeeding should be discontinued.
- History of allergy or hypersensitivity to oxaliplatin, irinotecan, leucovorin, fluorouracil, pegfilgrastim, or any excipients.
- History of Gilbert's disease or known genotype UGT1A1 \*28/\*28.
- Inflammatory disease of the colon or rectum, or severe uncontrolled diarrhea.
- Active or history of celiac disease.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Key Trial Info
Start Date :
May 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06048484
Start Date
May 10 2024
End Date
April 1 2027
Last Update
February 13 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwell Health R.J. Zuckerberg Cancer Center
Lake Success, New York, United States, 11042
2
Columbia University Irving Medical Center
New York, New York, United States, 10032
3
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27514
4
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States, 19104